Rolf GREMPLER,Odd-Erik JOHANSEN,Thomas KLEIN,Gerd LUIPPOLD,Michael MARK
申请号：
US15915396
公开号：
US20180193427A1
申请日:
2018.03.08
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions
